Levoleucovorin
Information
- Drug Name
- Levoleucovorin
- Description
- Entry(CIViC)
- 2
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| colorectal cancer |
VEGFA UNDEREXPRESSION ( ENST00000372055.9 ) VEGFA UNDEREXPRESSION ( ENST00000372055.9 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
2 | 25973082 | Detail |
| colorectal cancer | DKK1 NUCLEAR EXPRESSION DKK1 NUCLEAR EXPRESSION | B |
Predictive
|
Supports
|
Resistance |
N/A
|
3 | 25788273 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Decreased peri- and post-therapeutic expression of... | VEGFA |
VEGFA UNDEREXPRESSION ( ENST00000372055.9 ) VEGFA UNDEREXPRESSION ( ENST00000372055.9 ) |
Sensitivity | true | CIViC Evidence | detail |
| Nuclear expression of DICKKOPF-1 was identified in... | DKK1 | DKK1 NUCLEAR EXPRESSION DKK1 NUCLEAR EXPRESSION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04210115 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | February 28, 2020 | February 1, 2027 |
| NCT03698461 | Completed | Phase 2 | Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab | May 15, 2019 | October 24, 2023 |
| NCT04949256 | Recruiting | Phase 3 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) | July 28, 2021 | December 29, 2025 |
| NCT05253651 | Recruiting | Phase 3 | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | October 24, 2022 | April 30, 2028 |
| NCT05945823 | Recruiting | Phase 2 | Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | July 13, 2023 | May 2025 |
| NCT03222089 | Withdrawn | Phase 2 | Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC | July 20, 2017 | July 20, 2020 |